Zymride M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and increasing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The combination of these two agents offers complementary mechanisms of action, providing effective control of blood glucose levels in patients inadequately managed with diet and exercise alone. Zymride M 2 Tablet PR is designed for prolonged release, facilitating sustained therapeutic effects and improved patient compliance through reduced dosing frequency. It is recommended to be used alongside lifestyle modifications such as diet and exercise. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in those with conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia and gastrointestinal disturbances is essential during therapy. This combination therapy should be prescribed and adjusted under medical supervision to optimize glycemic control and minimize risks.